Search Page

1

Cite

Share

Chemical Development of Therapeutic Oligonucleotides.

Lundin KE, Gissberg O, Smith CIE, Zain R. Lundin KE, et al. Among authors: gissberg o. Methods Mol Biol. 2019;2036:3-16. doi: 10.1007/978-1-4939-9670-4_1. Methods Mol Biol. 2019. PMID: 31410788

Cite

Share

2

Cite

Share

Oligonucleotide Therapies: The Past and the Present.

Lundin KE, Gissberg O, Smith CI. Lundin KE, et al. Among authors: gissberg o. Hum Gene Ther. 2015 Aug;26(8):475-85. doi: 10.1089/hum.2015.070. Epub 2015 Aug 3. Hum Gene Ther. 2015. PMID: 26160334 Free PMC article. Review.

Cite

Share

3

Cite

Share

Sugar and Polymer Excipients Enhance Uptake and Splice-Switching Activity of Peptide-Dendrimer/Lipid/Oligonucleotide Formulations.

Saher O, Lehto T, Gissberg O, Gupta D, Gustafsson O, Andaloussi SE, Darbre T, Lundin KE, Smith CIE, Zain R. Saher O, et al. Among authors: gissberg o. Pharmaceutics. 2019 Dec 9;11(12):666. doi: 10.3390/pharmaceutics11120666. Pharmaceutics. 2019. PMID: 31835435 Free PMC article.

Cite

Share

4

Cite

Share

The ability of locked nucleic acid oligonucleotides to pre-structure the double helix: A molecular simulation and binding study.

Xu Y, Gissberg O, Pabon-Martinez YV, Wengel J, Lundin KE, Smith CIE, Zain R, Nilsson L, Villa A. Xu Y, et al. Among authors: gissberg o. PLoS One. 2019 Feb 12;14(2):e0211651. doi: 10.1371/journal.pone.0211651. eCollection 2019. PLoS One. 2019. PMID: 30753192 Free PMC article.

Cite

Share

5

Cite

Share

Optimizing DMPK Properties: Experiences from a Big Pharma DMPK Department.

Sohlenius-Sternbeck AK, Janson J, Bylund J, Baranczewski P, Breitholtz-Emanuelsson A, Hu Y, Tsoi C, Lindgren A, Gissberg O, Bueters T, Briem S, Juric S, Johansson J, Bergh M, Hoogstraate J. Sohlenius-Sternbeck AK, et al. Among authors: gissberg o. Curr Drug Metab. 2016;17(3):253-70. doi: 10.2174/1389200217666151210125637. Curr Drug Metab. 2016. PMID: 26651977 Review.

Cite

Share

6

Cite

Share

Agammaglobulinemia: causative mutations and their implications for novel therapies.

Berglöf A, Turunen JJ, Gissberg O, Bestas B, Blomberg KE, Smith CI. Berglöf A, et al. Among authors: gissberg o. Expert Rev Clin Immunol. 2013 Dec;9(12):1205-21. doi: 10.1586/1744666X.2013.850030. Expert Rev Clin Immunol. 2013. PMID: 24215410 Review.

Cite

Share

7

Cite

Share

CTG repeat-targeting oligonucleotides for down-regulating Huntingtin expression.

Zaghloul EM, Gissberg O, Moreno PMD, Siggens L, Hällbrink M, Jørgensen AS, Ekwall K, Zain R, Wengel J, Lundin KE, Smith CIE. Zaghloul EM, et al. Among authors: gissberg o. Nucleic Acids Res. 2017 May 19;45(9):5153-5169. doi: 10.1093/nar/gkx111. Nucleic Acids Res. 2017. PMID: 28334749 Free PMC article.

Cite

Share

8

Cite

Share

Delivery, Effect on Cell Viability, and Plasticity of Modified Aptamer Constructs.

Gissberg O, Zaghloul EM, Lundin KE, Nguyen CH, Landras-Guetta C, Wengel J, Zain R, Smith CI. Gissberg O, et al. Nucleic Acid Ther. 2016 Jun;26(3):183-9. doi: 10.1089/nat.2015.0592. Epub 2016 Feb 9. Nucleic Acid Ther. 2016. PMID: 26859550

Cite

Share

9

Cite

Share

Fast and efficient synthesis of Zorro-LNA type 3'-5'-5'-3' oligonucleotide conjugates via parallel in situ stepwise conjugation.

Gissberg OI, Jezowska M, Zaghloul EM, Bungsu NI, Strömberg R, Smith CI, Lundin KE, Honcharenko M. Gissberg OI, et al. Org Biomol Chem. 2016 Apr 14;14(14):3584-90. doi: 10.1039/c6ob00211k. Epub 2016 Mar 15. Org Biomol Chem. 2016. PMID: 26975344

Cite

Share

10

Cite

Share

Next-generation bis-locked nucleic acids with stacking linker and 2'-glycylamino-LNA show enhanced DNA invasion into supercoiled duplexes.

Geny S, Moreno PM, Krzywkowski T, Gissberg O, Andersen NK, Isse AJ, El-Madani AM, Lou C, Pabon YV, Anderson BA, Zaghloul EM, Zain R, Hrdlicka PJ, Jørgensen PT, Nilsson M, Lundin KE, Pedersen EB, Wengel J, Smith CI. Geny S, et al. Among authors: gissberg o. Nucleic Acids Res. 2016 Mar 18;44(5):2007-19. doi: 10.1093/nar/gkw021. Epub 2016 Feb 8. Nucleic Acids Res. 2016. PMID: 26857548 Free PMC article.

Cite

Share